Aspirin has become a widely accepted platelet function inhibitor and is used to prevent arterial occlusions in coronary cerebral and peripheral vascular disease. The results of clinical studies with aspirin in the area of peripheral arterial occlusive disease are critically reviewed. Two thienopyridine compounds, ticlopidine and clopidogrel, have been effectively used in the prevention of myocardial infarction and stroke in several clinical trials, especially in the recently published CAPRIE-trial. Potent new platelet function inhibitors recently were developed. Intravenous treatment with abciximab, a new platelet membrane glycoprotein IIb/IIIa-inhibitor, effectively prevented coronary reocclusions in patients with high-risk coronary events. A series of promising new oral IIb/IIIa- inhibitors have been developed and may become effective drugs in the prevention of reocclusions in patients with periph eral vascular disease and in coronary or cerebral vascular dis ease. Key Words: Antiplatelet agents—Aspirin—Peripheral arterial disease—Ticlopidine—Clopidogrel—GPIIb/IIIa inhibitor.
Get full access to this article
View all access options for this article.
References
1.
Otto JC, Smith WLProstaglandin endoperoxide synthases 1 and 2. J Lipid Med1995;12:139.
Kessels H., Beguin S., Nandree H., et al. Measurement of thrombin generation in whole blood—the effect of heparin and aspirin. Thromb Haemost1994;72:78.
4.
Barnett Hjm, Kaste M., Meldrum H., et al. Aspirin dose in stroke prevention. Beautiful hypotheses slain by ugly facts. Stroke1996; 27:588.
5.
Mori TA, Vandongen T., Douglas AJ, et al. Differential effect of aspirin on platelet aggregation in IDDM . Diabetes1992;41:261.
6.
Rimarachin JA , Jacobson JA, Szabo P., et al. Regulation of cyclooxygenase-2-expression in aortic smooth molecule cells. Arterioscler Thromb1994;46:154.
7.
Fitzgerald GA , Healy C., Daugherty J.Thromboxane A2 biosynthesis in human disease . Fed Proc1987;46:154.
8.
Best LC, McGuire MB, Jones Pbb, et al. Mode of action of dipyridamole on human platelets. Thromb Res1979; 16:367.
9.
Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation1995;91:2882.
10.
Tcheng JEGlycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol1996;78(suppl 3A):35.
11.
TheCAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study . Lancet1997;349:1429.
12.
Tcheng JE, Harrington RA, Kottke-Marchant K., et al. Multicenter, randomized, double blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation1995;91:2151.
13.
Verstraete M., Zoldhelyi P.Novel antithrombotic drugs in development . Drugs1995;49:856.
14.
Bollinger A. , Breddin K., Hess H., et al. Semiquantitative assessment of lower limb atherosclerosis from routine angiographic images . Atherosclerosis1981;38:339.
15.
Breddin HKDie Thrombozytenfunktion bei hämorrhagischen Diathesen, Thrombosen und Gefäβkrankheiten . Stuttgart, New York: Schattauer, 1968.
16.
Scharrer I. , Schepping M., Breddin K.Thromboseprophylaxe mit Aspirin?Klin Wschr1969;47:1318.
17.
Fitzgerald DE, Butterfield Wjh.A case of increased platelet anti-heparin factor in a patient with Raynaud's phenomena and gangrene treated by aspirin . Angiology1969;20:317.
18.
Vreeken J., van Aken WGSpontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet1971;2:1394.
19.
Biermer R., Boneu B., Guiraud B., et al. Aspirin and recurrent painful toes and fingers in thrombocythemia . Lancet1972 ; 1:432.
20.
Preston FE, IG Emmanuel, DA Winfield, et al. Essential thrombocythaemia and peripheral gangrene. Br Med J1974;3:548.
21.
Oblath RW, Buckley FO, Green RM, et al. Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole. Surgery1978;84:37.
22.
Ehringer H. , Marose L., Schöfl R., et al. Reduction of thrombotic layers on the new inner vessel wall following thrombendarterectomy (TEA) of the carotid artery by means of ASA (1.0 g/day) treatment. In: Maurer PC, Becker H, et al., eds. What is new in angiology—trends and controversies. München, Bern , Wien: Zuckschwerdt, 1986:298.
23.
Sinzinger H. , O'Grady J., Fitscha P.Platelet deposition on human atherosclerotic lesions is decreased by low dose aspirin in combination with dipyridamole . J Intern Med Res1988;16:39.
24.
Ehresmann U. , Alemany D., Loew D.Prophylaxe von Rezidivverschlüssen nach Revaskularisationseingriffen mit Acetylsalizylsäure. Med Welt1977;28:1157.
25.
Zekert F., Kohn P., Vormittag E.Eine randomisierte Studie über die postoperative Thromboseprophylaxe mit Acetylsalizylsäure . Med Welt1976;30:1372.
26.
Bollinger A. , Schneider E., Pouliadis G., et al. Thrombozytenfunktionshemmer und Antikoagulantien nach gefäßrekonstruktiven Eingriffen im femoro-poplitealen Bereich. Resultate einer prospektiven Studie . In: Breddin HK , ed. Thrombose und Atherogenese, Risikofaktoren bei gefäβchirurgischen Eingriffen. Witstrock, Baden-Baden , Köln , New York : Beckenthrombose . 1981:276.
27.
Brunner U., Bollinger A., Schneider E., et al. Endarteriektomie und autologer Venenbypass: Rezidivprophylaxe mit Aggregationshemmem und Antikoagulantien. In: Wagener O, Kubina VK, eds. Der Rezidivverschulβ nach Gefäβrekonstruktionen an der unteren Extremität . Wien: Egermann. 1979:99.
28.
Broomè A., Davidsson T., Eklöf B., et al. Effect of aggregation inhibitors on the rate of thrombectomy following arterial reconstructions with gore-tex prostheses: a retrospective study. Vasa1982;11:210.
29.
Albert JP, Regensburger D., Rudolf I., et al. Rezidivprophylaxe operativ korrigierter Arterienverschlüsse der unteren Extremitäten. Med Welt1982;33:1829.
30.
Kohler TR, Kaufmann IL, Kacoyanis G., et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96:462.
31.
Green RM, Roedersheimer RL, de Weese JA.Effects of aspirin and dipyridamole on expanded polytetrafluorethylene graft patency. Surgery1982;92:1016.
32.
Raithel D., Kaprzak P., Noppeney T.Rezidivprophylaxe nach femoropoplitealer Rekonstruktion mit PTFE-Prothesen . Med Welt1986; 37:644.
33.
Clyne Gac, Archer TJ, Atuhaire LK, et al. Randomized controlled trial of a short course of aspirin and dipyridamole (Persantin) for femoral grafts. Br J Surg1987;74:246.
34.
Edmonson RA , Cohen AT, Das SK, et al. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;914.
35.
Goldhaber SZ , Manson JE, Stampfer MJ, et al. Low dose aspirin and subsequent peripheral arterial surgery in the physicians health study . Lancet1992;340:143.
36.
Stein PD, Kantrowitz A.Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest1989 ;95:107S.
37.
Szilagy DE, Elliott JP, Hageman JH, et al. Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoropopliteal operations for atherosclerosis. Ann Surg1973 ;178:232.
38.
Fuster V., Chesebro JHRole of platelets and platelet inhibitors in aortocoronary vein graft disease . Circulation1986;73:227.
39.
Cunningham DA, Kumar B., Siegel BA, et al. Aspirin inhibition of platelet deposition at angioplasty sites: demonstration by platelet scintigraphy . Radiology1984;151:487.
40.
Goldman MD, Simpson D., Hawker RJ, et al. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoropopliteal grafts in man. Ann Surg1983 ;198:713.
41.
Gallino A., Mahler F., Propst P., et al. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow up. Circulation1984;70:619.
42.
Krepel VM, van Andel GJ, van Erp Wfm, et al. Percutaneous transluminal angioplasty of the femoropopliteal artery. Initial and long-term results. Radiology1985;156:325.
43.
Stokes KR, Strunk HM, Campbell DR, et al. Five year results of iliac and femoropopliteal angioplasty in diabetic patients. Radiology1990;174:977.
44.
Freimann DB , Spence R., Gatenby R., et al. Transluminal angioplasty of the iliac and femoral arteries. Results without anticoagulation . Radiology1981;141:337.
Zeitler E., Reichold J., Schoop W., et al. Einfluß von Acetylsalizylsäure auf das Frühergebnis nach perkutaner Rekanalisation arterieller Obliterationen nach Dotter. Dtsch Med Wschr1973;98:1285.
47.
Hess H., Müller-Fassbender H., Ingrisch H., et al. Verhütung von Wiederverschlüssen nach Rekanalisation obliterierter Arterien mit der Kathetermethode. Dtsch Med Wschr1978;103:1994.
48.
Staiger J., Mathias K., Friederich M., et al. Perkutane Katheterkanalisation (Dotter-Technik) bei peripherer arterieller Verschlußkrankheit. Herz/Kreisl.1980;9:383.
49.
Heiss HW, Just H., Middleton D., et al. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology1990 ;41:263.
50.
Ranke C., Creutzig A., Luska G., et al. Controlled trial of high versus low dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Invest1994;72:673.
51.
Weichert W. , Meentz H., Abt K., et al. Acetylsalicylic acid-reocclusion-prophylaxis after angioplasty (ARPA-Study). Vasa1994;23:57.
52.
Minar E., Ahmadi A., Koppensteiner R., et al. Comparison of effects of high dose and low dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation1995;91: 2167.
53.
Linke H.Langzeitprophylaxe mit ASS (Colfarit) bei arteriellen Angiopathien, insbesondere bei der Angiopathia diabetica. In: Marx R , Breddin HK, eds. Colfarit Symposium III. Köln: Bayer , 1975:88.
54.
Hess H., Keil-Kuri E.Theoretische Grundlagen der Prophylaxe obliterierender Arteriopathien mit Aggregationshemmern und Ergebnisse einer Langzeitstudie mit ASS (Colfarit) . In: Marx R, Breddin HK, eds. Colfarit-Symposium III. Köln: Bayer, 1975:80.
55.
Schoop W.Prognose und Prophylaxe der peripheren arteriellen Verschluβkrankheit . In: Triibestein C, ed. Arterielle Verschluβkrankheit und tiefe Bein-Beckenvenenthrombose. Stuttgart: Thieme, 1984 :172.
56.
Hess H., Mietaschk A., Deichsel G.Drug induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet1985;1:415.
57.
Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation1993;88:837.
58.
Ogren M., Jungquist G., Hedblad B., et al. Noninvasively detected carotid stenosis and ischemic heart disease in men with leg arteriosclerosis. Lancet1993 ;342:1138.
59.
Antiplatelet trialists' collaboration.Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J1994;308.
60.
Gent M., Blakely JA, Easton JD, et al. The CanadianAmerican ticlopidine study (CATS) in thromboembolic stroke. Lancet1989;1:1215.
61.
Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med1989;321:501.
62.
Ellis DJTreatment of intermittent claudication with ticlopidine, Abstr. 32nd, Meeting of the International Committee on Thrombosis and Haemostasis and the 9th Congress of the Mediterranean League against Thromboembolic Diseases , Jerusalem. June 1-6. 1986 .
63.
Arcan JC, Blanchard J., Boissel JP, et al. Multicenter double blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology1988;39:802.
64.
Balsano F., Coccheri S., Libretti A., et al. Ticlopidine in the treatment of intermittent claudication, a 21 month blind trial. J Lab Clin Med1989;114:84.
65.
Cloarec M., Arcan JC, Caillard Ph, et al. Double blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Angiologie1988;5(suppl 77):14.
66.
Boissel JP, Peyrieux JC, Destors JMIs it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?Thromb Haemost1989;62/2:681.
67.
Stiegler H. , Hess H., Mietaschk A., et al. Einfluß von Ticlopidin auf die periphere obliterierende Arteriopathie. Dtsch Med Wschr1984; 109:1240.
68.
Janzon L., Bergqvist D., Boberg J., et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, Swedish Ticlopidine Multicenter Study. J Intern Med1990;227:301.
69.
Bergqvist D. , Almgren B., Dickinson JPReduction of requirement for leg vascular surgery during long term treatment of claudicant patients with ticlopidine: results of Swedish ticlopidine Multicenter Study (STIMS) . Eur J Vasc Endovasc Surg1995;10:69.
70.
CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ichaemic events (CAPRIE). Lancet1996 ;348:1329.
71.
Colombo A., Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation1995;91:1677.
72.
Garcia-Cantu E., Spaulding C., Corcos T., et al. Stent implantation in acute myocardial infarction. Am J Cardiol1996;77:454.
73.
Serruys PW, Emanuelsson H., van der Giessen W., et al. Heparin coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent II pilot study. Circulation1996;93:412.
74.
Thebault JJ , Blatrix CE, Blanchard JF, et al. The interactions of ticlopidine and aspirin in normal subjects. J Intern Med Res1977; 5:405.
